Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
7.34
-0.71 (-8.82%)
At close: Mar 13, 2026, 4:00 PM EDT
7.89
+0.55 (7.49%)
After-hours: Mar 13, 2026, 7:53 PM EDT
Lipocine Employees
Lipocine had 16 employees as of December 31, 2024. The number of employees decreased by 1 or -5.88% compared to the previous year.
Employees
16
Change (1Y)
-1
Growth (1Y)
-5.88%
Revenue / Employee
$123,542
Profits / Employee
-$601,719
Market Cap
53.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Sep 30, 2022 | 17 | 4 | 30.77% |
| Jun 30, 2022 | 15 | 2 | 15.38% |
| Mar 31, 2022 | 13 | 0 | - |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Sep 30, 2021 | 13 | 2 | 18.18% |
| Jun 30, 2021 | 13 | - | - |
| Mar 31, 2021 | 13 | 1 | 8.33% |
| Dec 31, 2020 | 11 | -1 | -8.33% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 124 |
| Acrivon Therapeutics | 78 |
| Kezar Life Sciences | 55 |
| GeoVax Labs | 17 |
| Rallybio | 15 |
| Instil Bio | 14 |
| MAIA Biotechnology | 13 |
| OS Therapies | 5 |
LPCN News
- 5 days ago - Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 - PRNewsWire
- 25 days ago - Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PRNewsWire
- 7 weeks ago - Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 2 months ago - Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 3 months ago - Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PRNewsWire
- 4 months ago - Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) - PRNewsWire
- 4 months ago - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 - PRNewsWire
- 4 months ago - Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek® - PRNewsWire